Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics

Published: December 2010
No. of Pages: 124

Price

Report Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics” that provides key data, information and analysis of the major trends and issues in Personalized Medicine Market. The report provides a comprehensive insight into the role of Human Genomics and Proteomics to challenge traditional therapeutics. The report also provides a detailed analysis of market characterization of personalized medicine market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the patent landscape for human genomics and proteomics and provides comprehensive analysis.

Scope

The scope of the report includes:

Detailed overview of Personalized Medicine Market in pharmaceutical industry along with their use, efficiency and limitation.
Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.
Key market drivers and restraints shaping the Personalized Medicine Market.
Competitive landscape analysis with competitive profiling of leading companies.
Analysis of partnership deals from 2006 to 2010
Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Develop better strategies for personalized medicine market research by understanding the market dynamics.
Develop market-entry and market expansion strategies by identifying the key development area
Understand the factors shaping the Personalized Medicine Market
For understanding the role of Human Genomics and Proteomics to challenge traditional therapeutics.
Identify the key players best positioned to take the advantage of the opportunities in the global market.
Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Personalized Medicine Market: Market Overview
2.1 Introduction
2.1.1 Potential Applications of Personalized Medicine
2.2 GBI Research Report Guidance

3 Personalized Medicine Market: Drivers and Barriers
3.1 Drivers
3.1.1 Increase in healthcare costs
3.1.2 Advantages over conventional drug discovery methods
3.1.3 Patient compliance
3.1.4 Early detection of disease
3.1.5 Better regulatory norms and validation procedures encourage growth of the personalized medicine market
3.2 Barriers
3.2.1 Payer Reimbursement Issues
3.2.2 Ethical Issues
3.2.3 Medical Information Technology
3.2.4 Awareness Gap - Lack of Physician Education and Awareness about Novel Technologies
3.2.5 Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector

4 Personalized Medicine Market - Personalized Therapeutics and Diagnostics
4.1 Personalized Therapeutics - Drug Profiles
4.1.1 Herceptin (trastuzumab)
4.1.2 Erbitux (cetuximab)
4.1.3 Gleevec (imatinib)
4.1.4 Zyprexa (olazapine)
4.1.5 Lipitor (atorvastatin)
4.1.6 Celebrex (celecoxib)
4.1.7 Tarceva (erlotinib)
4.1.8 Rituxan (rituximab)
4.1.9 Plavix (clopidogrel bisulfate)
4.1.10 Risperdal (risperidone)
4.1.11 Vectibix (Panitumumab)
4.1.12 Coumadin (Warfarin)
4.1.13 Iressa (Gefitinib)
4.1.14 Sprycel
4.1.15 Camptosar
4.2 Companion Diagnostics
4.2.1 Selected Companion Diagnostics Employed in Personalized Healthcare
4.3 Biomarkers
4.3.1 Biomarkers in Cancer Research
4.3.2 Market Size and Forecasts
4.3.3 Segmentation by Indication

5 Personalized Medicine Market: Selected Pipeline Product Profiles
5.1 PF-4948568 (Pfizer)
5.1.1 Overview
5.1.2 Mechanism of Action
5.1.3 Clinical Study Details
5.2 PF-02341066 + Erlotinib (Pfizer)
5.2.1 Overview
5.2.2 Mechanism of Action
5.2.3 Clinical study details
5.3 PF-299804 (Pfizer)
5.3.1 Overview
5.3.2 Mechanism of action
5.3.3 Clinical study details
5.4 CEP-701 (Cephalon Inc.)
5.4.1 Overview
5.4.2 Mechanism of action
5.4.3 Clinical study details
5.5 TBR-652 (Tobira Therapeutics, Inc)
5.5.1 Overview
5.5.2 Mechanism of action
5.5.3 Clinical study details
5.6 Brivanib (Bristol-Myers Squibb)
5.6.1 Overview
5.6.2 Mechanism of action
5.6.3 Clinical study details
5.7 Ipilimumab (Bristol-Myers Squibb)
5.7.1 Overview
5.7.2 Mechanism of Action
5.7.3 Clinical Study Details
5.8 BiovaxID (Accentia Biopharmaceuticals, Inc.)
5.8.1 Overview
5.8.2 Mechanism of Action
5.8.3 Clinical Study Details

6 Personalized Medicine Market: Research Trends in Personalized Medicine

7 Personalized Medicine Market: Competitive Landscape
7.1 Competitive Profiling
7.2 Clarient, Inc.
7.2.1 Business Description
7.2.2 Pipeline
7.2.3 Major Products
7.2.4 Partnership and Merger and Acquisition (M&A) Deals
7.3 Qiagen N.V.
7.3.1 Business Description
7.3.2 Pipeline
7.3.3 Major Products
7.3.4 Partnership and M&A Deals
7.4 Laboratory Corporation of America Holdings
7.4.1 Business Description
7.4.2 Pipeline
7.4.3 Major Products
7.4.4 Partnership and M&A Deals
7.5 bioMerieux S.A.
7.5.1 Business Description
7.5.2 Pipeline
7.5.3 Major Products
7.5.4 Partnership and M&A Deals
7.5.5 Partnership and M&A Deals
7.6 Pfizer
7.6.1 Business Overview
7.6.2 Partnership and M&A Deals
7.7 Eli Lily and Company
7.7.1 Business Overview
7.7.2 Partnership and M&A deals
7.8 Novartis
7.8.1 Business Overview
7.8.2 Partnership and M&A Deals
7.9 F. Hoffman La Roche
7.9.1 Business Overview
7.9.2 Diagnostics
7.9.3 Pharmaceuticals
7.9.4 Partnership and M&A Deals
7.10 Bristol-Myers Squibb
7.10.1 Business Overview
7.10.2 Partnership and M&A deals
7.11 Merck KGaA
7.11.1 Business Overview
7.11.2 Partnership and M&A deals
7.12 Dako Denmark A/S
7.12.1 Business Overview
7.12.2 Partnership and M&A deals

8 Personalized Medicine Market: Conclusion

9 Personalized Medicine Market: Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

1.1 List of Tables

Table 1: Herceptin - Snapshot 2010
Table 2: Herceptin, Global, Revenues ($m) 2007-2009
Table 3: Erbitux - Snapshot 2010
Table 4: Erbitux, Global, Revenues ($m) 2007-2009
Table 5: Gleevec - Snapshot 2010
Table 6: Gleevec, Global, Revenues ($m) 2007-2009
Table 7: Zyprexa - Snapshot 2010
Table 8: Zyprexa, Global, Revenues ($m) 2007-2009
Table 9: Lipitor - Snapshot 2010
Table 10: Lipitor, Global, Revenues ($m) 2007-2009
Table 11: Celebrex - Snapshot 2010
Table 12: Celebrex, Global, Revenues ($m) 2007-2009
Table 13: Tarceva - Snapshot 2010
Table 14: Tarceva, Global, Revenues ($m) 2007-2009
Table 15: Rituxan - Snapshot 2010
Table 16: Rituxan, Global, Revenues ($m) 2007-2009
Table 17: Rituxan, Global, Revenues 2007-2009
Table 18: Plavix - Snapshot 2010
Table 19: Plavix, Global, Revenues ($m) 2007-2009
Table 20: Risperdal - Snapshot 2010
Table 21: Risperdal, Global, Revenues ($m) 2007-2009
Table 22: Vectibix - Snapshot 2010
Table 23: Coumadin - Snapshot 2010
Table 24: Iressa - Snapshot 2010
Table 25: Sprycel - Snapshot 2010
Table 26: Camptosar - Snapshot 2010
Table 27: Personalized Medicine Market, List of Selected Personalized Diagnostics and Therapeutics, 2010*
Table 28: Personalized Medicine Market, Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007-2016
Table 29: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Breast Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 30: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Prostate Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 31: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Lung Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 32: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Colorectal Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 33: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Cervical Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 34: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Head and Neck Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 35: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 36: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Ovarian Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 37: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Stomach Cancer Biomarkers Market Revenues ($m), 2007-2016
Table 38: Personalized Medicine Market, Clarient, Pipeline, August 2010
Table 39: Personalized Medicine Market, Clarient, Major M&A Deals, 2005-2010
Table 40: Personalized Medicine Market, Clarient, Partnership Deals, 2006-2010
Table 41: Personalized Medicine Market, QIAGEN, Pipeline, August 2010
Table 42: Personalized Medicine Market, QIAGEN, Major M&A Deals, 2005-2010
Table 43: Personalized Medicine Market, QIAGEN, Partnership Deals, 2006-2010
Table 44: Personalized Medicine Market, Laboratory Corporation of America Holdings, Pipeline, August 2010
Table 45: Personalized Medicine Market, Laboratory Corporation of America Holdings, Major M&A Deals, 2005-2010
Table 46: Personalized Medicine Market, Laboratory Corporation of America Holdings, Partnership Deals, 2006-2010
Table 47: Personalized Medicine Market, bioMerieux, Pipeline, August 2010
Table 48: Personalized Medicine Market, bioMerieux, Major M&A Deals, 2005-2010
Table 49: Personalized Medicine Market, bioMerieux, Partnership Deals, 2006-2010
Table 47: Personalized Medicine Market, Biomoda, Partnership Deals, 2006-2010

1.2 List of Figures

Figure 1: Personalized Medicine Market, Potential Applications of Personalized Medicine
Figure 2: Personalized Medicine Market, Market Drivers and Restraints, 2010
Figure 3: Herceptin, Global, Revenues ($m) 2007-2009
Figure 4: Herceptin - SWOT 2010
Figure 5: Erbitux, Global, Revenues ($m) 2007-2009
Figure 6: Erbitux - SWOT 2010
Figure 7: Gleevec, Global, Revenues ($m) 2007-2009
Figure 8: Gleevec - SWOT 2010
Figure 9: Zyprexa, Global, Revenues ($m) 2007-2009
Figure 10: Zyprexa - SWOT 2010
Figure 11: Lipitor, Global, Revenues ($m) 2007-2009
Figure 12: Lipitor - SWOT 2010
Figure 13: Celebrex, Global, Revenues ($m) 2007-2009
Figure 14: Celebrex - SWOT 2010
Figure 15: Tarceva, Global, Revenues ($m) 2007-2009
Figure 16: Tarceva - SWOT 2010
Figure 17: Rituxan, Global, Revenues ($m) 2007-2009
Figure 18: Rituxan - SWOT 2010
Figure 19: Plavix, Global, Revenues ($m) 2007-2009
Figure 20: Plavix- SWOT 2010
Figure 21: Risperdal, Global, Revenues ($m) 2007-2009
Figure 22: Risperdal - SWOT 2010
Figure 23: Personalized Medicine Market, Biomarkers in Cancer Research, 2010
Figure 24: Personalized Medicine Market, Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007-2016
Figure 25: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Market Segmentation by Indication, 2009
Figure 26: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Breast Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 27: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Prostate Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 28: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Lung Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 29: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Colorectal Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 30: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Cervical Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 31: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Head and Neck Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 32: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 33: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Ovarian Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 34: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Stomach Cancer Biomarkers Market Revenues ($m), 2007-2016
Figure 35: Research and Innovation Trends in Personalized Medicine
Figure 36: Personalized Medicine Market, Global, Geographic Landscape, 2009

Published By: GBI Research
Product Code: GBI Research1115

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)
In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the r...
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug,...
Product Profiles: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation
IntroductionThe targeted therapies class boasts several of the top-selling anticancer brands, and has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade, several blockbuster targete...
Market and Product Forecasts: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation
IntroductionThe targeted therapies class boasts several of the top-selling anticancer brands, and has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade, several blockbuster ta...
Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets
INTRODUCTIONSTUDY GOALS AND OBJECTIVESThis BCC Research report, , provides an overview of the current ...
The Future of Molecular Diagnostics: Innovative technologies driving market opportunities in personalized medicine
Molecular diagnostics, essentially the analysis of DNA and RNA at the molecular level, is a fast-growing business, made possible by the growing understanding of the human genome, which has spurred growth...
Combination Drug Diagnostics: Fueling Growth of Personalized Medicine
Report Description:The focus of this report is on drug/diagnostic combinations -- drugs used to treat patients, and ondiagnostic tests that can provide information about how a patient may respond to treatment with tha...
Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
The key factor in the current scenario for next-generation omics-based diagnostic technologies is the level of accuracy in the results, followed by the capacity to detect early, and cost. Cost currently remains a major constraint, as people and he...
Stakeholder Opinions: Biomarkers in Rheumatology - Awaiting the next step towards personalized medicine
IntroductionThe growing recognition from companies of the applied benefits from biomarkers in rheumatology has spurred commercial interest in this field. Despite the lack of major advancements, the hope remains that soon rh...
Pharmacodiagnostics and Personalized Medicine 2009 Markets, Challenges, Forecasts and Key Players
Pharmacodiagnostics are considered the pathway to what has been termed "personalized medicine," the use of molecular analysis to achieve optimum medical outcomes in the management of a patient’s disease or predisposition to disease.

Connect With Us

Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option

Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: